An interventional study of Digital health interventions in Noncommunicable Diseases and COVID-19, sponsored by University of Toronto. Completed at 1 site in Pakistan. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Toronto · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled trial aims to implement and evaluate a comprehensive package of digital health interventions for integrated COVID-non-communicable diseases (NCDs) care to manage NCDs in primary care facilities in rural Pakistan. The main questions it aims to answer are 1) whether such interventions are effective; 2) how they were implemented; and 3) whether such interventions are cost-effective.
30 rural health centers in Punjab Province, Pakistan will be randomized into two groups. The intervention group will provide a comprehensive package of digital health interventions to connect patients, patient champions, and public health providers to improve the management of NCDs during the pandemic, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Usual care will be provided in the control group. Researchers will compare the two groups to see if the systolic blood pressure can be controlled better in the intervention group at 12 months.
146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.
This study's enrollment of 1,965 is above the median of 478 across 97 interventional studies indexed under Noncommunicable Diseases.
Browse Noncommunicable Diseases studies →University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A comprehensive package of digital health interventions to connect patients, patient champions and public health providers to improve the management of non-communicable diseases (NCDs) during the pandemic will be implemented, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Patient champions are experienced patients who can provide peer support.
Other: Digital health interventions
Usual care, which is routine hypertension and diabetes diagnosis and treatment under the World Diabetes Foundation (WDF) project will be implemented. The WDF project provides initial Zoom-based training of NCD care to rural health center (RHC) staff, but no tele-mentorship is offered. Under the usual care, patients with hypertension or diabetes are required to visit RHCs every month to renew their medications and measure their blood pressure. No other interventional components will be implemented in the control arm.
Described in arm descriptions.
Systolic blood pressure (mmHg) measured in the rural health center
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Diastolic blood pressure (mmHg) measured in the rural health center
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Percentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetes
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Random blood glucose (mmol/L)
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Body mass index (BMI)
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Number of consultations with RHC doctors, including both in-person and virtual consultations
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.
Time frame: During the 12-month intervention period
Systolic and diastolic blood pressure
Time frame: At 6 months
Proportion of patients who have had at least three doses of COVID vaccinations
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months; consequently, the timing of the outcome measure was rescheduled to Month 12.
Time frame: At 12 months
Proportion of participants been admitted to district hospitals for any reasons
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.
Time frame: During the 12-month intervention period
All-cause mortality rate
Following the Trial Steering Committee's decision in October 2023, the intervention period was extended from 10 to 12 months.
Time frame: During the 12-month intervention period
Plan to share: Yes — According to the ethical agreements, the data is only available for research purpose of the study team. Individual patient data cannot be posted and downloaded in a public data depository. Anonymous data can be shared upon request to the study contacts with joint ethics application to the University of Toronto.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication in peer-reviewed journals.
Access criteria: The research team will aim to publish them in open access journals as priority so that all other researchers will freely access to them.
Ran from Feb 2023 to primary completion in May 2024, 15 months.
Of 79 non-industry interventional studies with no phase under Noncommunicable Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 15 months is below that.
Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 7 and three quarters within 30.
Noncommunicable Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Jan 2023 → Feb 2023, primary completion Feb 2024 → May 2024 and completion Feb 2024 → Aug 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.